ACE-031 is an investigational soluble ActRIIB-Fc fusion protein designed to bind myostatin and related ligands. Human studies used defined clinical material in healthy volunteers and ambulatory boys with Duchenne muscular dystrophy; a separate preclinical paper examined a soluble ActRIIB receptor construct. Those findings do not establish interchangeability with an independently sourced batch. The current wholesale price list contains one entry marked 1 / Injectable, but the dosage unit and exact construct must be confirmed before ordering.
| Class | Investigational soluble activin receptor type IIB Fc-fusion protein. |
| Construct identity | Confirm the ActRIIB extracellular-domain boundaries, Fc design, expression host, glycosylation profile and intact mass. |
| Listed presentation | 1 / Injectable. The current wholesale price list does not state the dosage unit. |
| Purity and aggregation | Use orthogonal batch methods such as SEC and SDS-PAGE; a single area-purity percentage does not establish monomer state or biological activity. |
| Activity | Confirm the ligand-binding or cell-based activity method and acceptance criteria for the allocated batch. |
| Formulation and handling | Confirm buffer, excipients, endotoxin result, shipping temperature and in-use window for the supplied vial. |
Wholesale from $6.12
Published wholesale tiers apply when the order reaches 100+ total units; the tier is selected by quantity of each SKU. Smaller total orders are quoted separately.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 1 / Injectable | $8.16 | $7.14 | $6.12 |
ACE-031 is an Fc-fusion biologic. The product name and a generic purity figure are not enough to establish construct identity, monomer state or activity.
Request the expressed domain boundaries, Fc sequence, expression host, glycosylation information and an intact-mass or peptide-mapping identity result.
Review SEC and SDS-PAGE results alongside a relevant ligand-binding or cell-based activity assay. Confirm the acceptance criteria used for the batch.
Confirm fill amount, dosage unit, buffer, excipients, endotoxin reporting, shipping temperature and reconstituted-use window.
Published ACE-031 studies used defined investigational material. Their outcomes are not a specification for independently supplied material.
Attie et al. (2012). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve. DOI: 10.1002/mus.23539
Study scope: Healthy volunteers in a single ascending-dose clinical study. Defined investigational ACE-031 ActRIIB-Fc clinical material.
What it supports: Supports discussion of early human tolerability, pharmacology and muscle-related measures after a single administration.
Boundary: It does not establish chronic therapeutic efficacy, outcomes in other populations or equivalence with a supplier batch.
Campbell et al. (2016). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve. DOI: 10.1002/mus.25268
Study scope: Ambulatory boys with Duchenne muscular dystrophy. Defined investigational ACE-031 clinical material and the trial's dosing schedule.
What it supports: Supports a bounded description of the studied pediatric DMD population, measured outcomes and safety observations.
Boundary: The results cannot be generalized to healthy adults, other diseases, unspecified dosing or independently sourced ACE-031.
Cadena et al. (2010). Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. Journal of Applied Physiology. DOI: 10.1152/japplphysiol.00866.2009
Study scope: An animal skeletal-muscle model. A soluble activin type IIB receptor construct used in the study; it must not be assumed to be identical to any supplier batch.
What it supports: Supports discussion of soluble ActRIIB-receptor biology and skeletal-muscle effects in the reported preclinical model.
Boundary: It is not human clinical evidence and does not prove that a differently sourced Fc-fusion construct is equivalent.
ACE-031 is an investigational soluble ActRIIB-Fc fusion protein designed as a ligand trap for myostatin and related TGF-beta-family ligands.
The current wholesale price list contains one entry marked 1 / Injectable. The dosage unit and exact construct are not stated and must be confirmed in the quote.
For orders meeting 100+ total units, the listed ACE-031 tiers are $8.16 for 10–24 units of the SKU, $7.14 for 25–49 and $6.12 for 50+ units.
ACE-031 is an Fc-fusion protein. Buyers also need construct identity, monomer and aggregate data, glycosylation information and a relevant activity result.
No. The studies used defined investigational ACE-031 material and study-specific formulations. They do not establish batch interchangeability.
Confirm the buffer, excipients, fill amount, endotoxin result, shipping temperature, allowed freeze-thaw exposure and the in-use window for the supplied batch.